Biogen’s Alzheimer drug slows mental decline

March 22, 2015 10:01 PM

9 0

Biogen Idec Inc (NASDAQ:BIIB) drug that attacks plaque buildup in the human brain slowed cognitive decline in patients that were in early phase of Alzheimer disease. The results were revealed in a small, early-stage study carried out by the company that tracked patients over 54 weeks. The news took Biogen’s share price to all-time highs.

In December, Biogen stated that its drug named ‘aducanumab’ resulted in a statistically noteworthy effect on cognition and intends to commence a late-stage trial later this year that will include over 1,000 patients. It used two cognitive tests in early stage trial to evaluate aducanumab’s clinical ...

Read more

To category page

Loading...